JINLING PHARM. branch received the acceptance notice for Olaratumab tablets
I'm PortAI, I can summarize articles.
JINLING PHARM.'s subsidiary Nanjing JINLING Pharmaceutical Factory recently received the acceptance notice from the National Medical Products Administration for the application of domestic production drug registration clinical trials for Elagolix tablets. Elagolix is a GnRH antagonist that was approved by the FDA in 2018, specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials go smoothly, it will enhance the company's product line and competitiveness
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments